TG Therapeutics, Inc.
TGTX- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001001316
In the last 90 days, TG Therapeutics, Inc. insiders filed 0 open-market purchases and 1 sale; 430 institutions reported holding it in 13F filings for Q2 2026, worth $6.10B in total; no superinvestor holds it.
Superinvestors holding TGTX, Q2 2026
No superinvestor reported holding TGTX in Q2 2026.
Moves by quarter
Superinvestors that opened, added to, trimmed or sold out of TGTX each quarter, comparing shares with the quarter before. A superinvestor that didn't file for a quarter isn't listed, and isn't counted as selling.
Q2 2024
0 superinvestors holding at quarter end
- Sold out
- Duquesne Family Office
Q1 2024
1 superinvestor holding at quarter end
Q1 2023
0 superinvestors holding at quarter end
- Sold out
- Maverick Capital
Q4 2022
1 superinvestor holding at quarter end
- Reduced
- Maverick Capital (−43.9%)
Q3 2022
1 superinvestor holding at quarter end
- Added
- Maverick Capital (+14.1%)
Q2 2022
1 superinvestor holding at quarter end
- Added
- Maverick Capital (+1.0%)
Q1 2022
1 superinvestor holding at quarter end
- Added
- Maverick Capital (+10.7%)
Q4 2021
1 superinvestor holding at quarter end
- Added
- Maverick Capital (+83.1%)
Q3 2021
1 superinvestor holding at quarter end
- Added
- Maverick Capital (+16.9%)
Q2 2021
1 superinvestor holding at quarter end
- Reduced
- Maverick Capital (−5.1%)